Eli Lilly will raise the list price in the UK of its weight-loss and type 2 diabetes treatment Mounjaro by 170% to be in line ...

Eli Lilly (LLY) has entered into a deal worth up to $1.3 billion with drug discovery company Superluminal Medicines to ...

Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion to ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Eli Lilly will increase the UK price of its Mounjaro treatment by 170% to match European markets. Despite Novo Nordisk's ...

Eli Lilly & Co. is raising the list price for its obesity shot in the UK, as the pharma industry comes under pressure from US ...

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly ( NYSE: LLY) will raise the cost of its GLP-1/GIP receptor agonist Mounjaro (tirzepatide), approved for type 2 ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Last and least, I look at the drug stocks and I can’t believe how awful they really are, with now Eli Lilly last joining the ...